Juan Bailey
Infectious Disease · New York, NYNPI 1205817624
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 66.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $6,683 and has fallen 71.0% since, to $1,938 in 2025. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $59.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$12K
- Viiv Healthcare Company$4K
- Johnson & Johnson$773
- Janssen Products, LP$623
- Hologic Sales And Service, LLC$237
- AbbVie$226
- plus $294 from 6 others
Across 2 payments — averaging $3375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$7K
What the payments were for
- Consulting fees$7,18039%
- Travel & lodging$1,90510%
- Food & beverage$9,22750%
- Education$3102%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 107 | $12,313 |
| Viiv Healthcare Company | 147 | $4,155 |
| Johnson & Johnson(2 entities) | 38 | $773 |
| Janssen Products, LP | 6 | $623 |
| Hologic Sales And Service, LLC | 1 | $237 |
| AbbVie | 5 | $226 |
| AstraZeneca | 1 | $122 |
| Janssen Scientific Affairs, LLC | 4 | $56 |
| Theratechnologies Inc. | 1 | $47 |
| Merck | 2 | $34 |
| GSK | 1 | $23 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,622 in reported general payments places this provider in the 90th percentile of 799 infectious disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 123 | $503,006 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 19 | $83,310 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 15 | $71,768 |
| PrezcobixDarunavir/Cobicistat | 26 | $59,868 |
| DovatoDolutegravir Sodium/Lamivudine | 16 | $59,123 |
| TivicayDolutegravir Sodium | 24 | $51,833 |
| DescovyEmtricitabine/Tenofov Alafenam | 23 | $48,467 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $44,715 |
| JanuviaSitagliptin Phosphate | 34 | $36,133 |
| JardianceEmpagliflozin | 19 | $25,231 |
| IsentressRaltegravir Potassium | 13 | $24,214 |
| VascepaIcosapent Ethyl | 52 | $20,571 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 37 | $20,448 |
| TrulicityDulaglutide | 11 | $17,099 |
| OzempicSemaglutide | 18 | $16,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $12,313 | $596,188158 claims |
| Viiv Healthcare CompanyTriumeq, Dovato, Tivicay | $4,155 | $182,72455 claims |
| Janssen Products, LPSymtuza | $623 | $83,31019 claims |
| MerckJanuvia, Isentress, Janumet Xr | $34 | $80,79584 claims |
| Johnson & JohnsonPrezcobix | $773 | $59,86826 claims |
| Lilly USA, LLCTrulicity | $12 | $17,09911 claims |
| AbbVieLinzess | $226 | $15,54527 claims |
| GSKIncruse Ellipta, Arexvy, Shingrix | $23 | $8,88534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 799 infectious disease providers in New York.
Other infectious disease in New York
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Genovefa PapanicolaouNew York$209K
- Michelle CespedesNew York$125K
- Donald KaminskyNew York$120K
- Judith AbergNew York$104K
- Thomas WalshNew York$98K
- Stuart HaberNew York$73K
- Michael GaisaNew York$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.